More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to…
eTurboNews Els articles són només per a subscriptors. La subscripció és GRATIS.
Els subscriptors inicien sessió aquí Feu clic aquí per subscriure-us GRATIS
Els subscriptors inicien sessió aquí Feu clic aquí per subscriure-us GRATIS
QUÈ TREURE D'AQUEST ARTICLE:
- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.
- ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting.
- Lebrikizumab, an investigational IL-13 inhibitor, also led to….
